[This Week's IPO] November First Week Bookbuilding and Subscription Schedule

In the first week of this month (November), CK Solution and Onconic Therapeutics will conduct demand forecasting targeting institutional investors. Nomus, Dotmill, Orum Therapeutics, Three Billion, Escam, MOT, Witz, and Synapsoft are preparing for general subscription.

◆CK Solution= Established in 2004, CK Solution is a specialized company in dry room systems for the secondary battery industry. It is expanding its business globally in North America, Europe, and East Asia alongside the three major domestic secondary battery companies. Additionally, based on accumulated technology and know-how in the refrigeration and air conditioning field, it is advancing dry room systems and clean rooms together, expanding its business into semiconductors, bio, and data centers.

It plans to offer a total of 3,145,000 shares. The expected public offering price band is KRW 15,700 to KRW 18,000 per share. Demand forecasting for institutional investors will be conducted from the 4th to the 8th, followed by general subscription on the 13th and 14th, with a planned listing on the KOSPI market. The lead underwriter is NH Investment & Securities.

◆Onconic Therapeutics= Onconic Therapeutics launched and began sales of the domestic 37th new drug P-CAB (Potassium-Competitive Acid Blocker) formulation ‘Jacubojeong,’ expected to replace the existing PPI (Proton Pump Inhibitor) in the peptic ulcer drug market, starting from the 1st of this month.

It plans to offer a total of 1,550,000 shares. The expected public offering price per share is KRW 16,000 to KRW 18,000. Demand forecasting will be conducted from the 4th to the 8th, followed by general subscription on the 14th and 15th, aiming for a KOSDAQ listing within the year. The lead underwriter is NH Investment & Securities.

◆Nomus= Nomus finalized its public offering price at the upper end of the expected band (KRW 27,200 to KRW 30,200) at KRW 30,200. A total of 1,042 domestic and international institutions participated in the demand forecasting, recording a competition rate of 288 to 1. The total public offering amount is KRW 34.1 billion, and the market capitalization after listing is approximately KRW 323.4 billion. General subscription will be held from the 4th to the 5th, with a planned listing on the KOSDAQ market on the 12th. The lead underwriter is Daishin Securities.

Nomus initially introduced content that conveyed the know-how and philosophy of various artists through Wonderwall Class and directly plans and produces artists’ MD and brands, selling and distributing them through its own shopping mall, providing an integrated process including customer service.

◆Dotmill= Dotmill finalized its public offering price at the upper end of the expected band (KRW 11,000 to KRW 13,000) at KRW 13,000. A total of 2,151 domestic and international institutions participated in the demand forecasting, recording a competition rate of 1,082 to 1. Based on the public offering price, the total public offering amount is KRW 15.6 billion, and the market capitalization after listing is approximately KRW 118.9 billion. The general subscription for retail investors will be conducted over two days from the 4th to the 5th, with a planned listing on the 13th. The lead underwriter is Mirae Asset Securities.

Since its establishment in 2015, Dotmill has rapidly grown by presenting immersive content that combines analog and immersive media technology, creating a new paradigm. Its main business areas include project orders and the construction and operation of its own theme parks using immersive media. Leveraging its one-stop solution strength, it creates diverse business opportunities encompassing B2B, B2G, and B2C customers, standing out in the immersive media market.

◆Orum Therapeutics= The expected public offering price range per share is KRW 30,000 to KRW 36,000. Demand forecasting was conducted until the 30th of last month, and the public subscription will be held over two days on the 5th and 6th. The lead underwriter is Korea Investment & Securities.

Orum Therapeutics is a leading bio company in the antibody-drug conjugate (ADC) field based on the dual precision targeted protein degradation approach ‘TPD²®’. ADC is a next-generation modality that selectively delivers targeted protein degraders (TPD) to target cells via antibodies and degrades target proteins within cells.

◆Three Billion= Three Billion finalized its public offering price at KRW 4,500, within the expected band (KRW 4,500 to KRW 6,500). A total of 809 institutions participated in the final demand forecasting, recording a competition rate of 254.6 to 1. The public offering amount is KRW 14.4 billion, and the market capitalization after listing is approximately KRW 141.5 billion. General subscription for retail investors will be held over two days on the 5th and 6th, with a planned listing on the KOSDAQ on the 14th. The lead underwriter is Korea Investment & Securities.

Three Billion’s core technology is AI (Artificial Intelligence), which interprets the pathogenicity of 100,000 genetic variants of patients with 99.4% accuracy within 5 minutes and identifies the top 5 causative genetic variants of patients’ diseases with 98.1% accuracy. Based on this technology, it operates rare genetic disease diagnostic tests, supports specific disease diagnostic tests, data-based diagnostic tests, and SaaS-type software subscription services.

◆Escam= The expected public offering price is KRW 13,000 to KRW 14,600, with a public offering amount of KRW 25.3 billion to KRW 28.4 billion. Demand forecasting was conducted until the 1st, and general subscription will be held on the 7th and 8th. The lead underwriter is NH Investment & Securities.

Escam, established in 2014, is a specialized company in OLED material synthesis and purification. The company can realize ultra-high purity materials of 99.9% through advanced sublimation purification technology, supplying high-quality materials that meet the trends of high performance, high efficiency, and long lifespan.

◆MOT= The expected public offering price is KRW 12,000 to KRW 14,000. Demand forecasting will be conducted until the 4th, and general subscription will be held over two days on the 7th and 8th. The lead underwriter is Korea Investment & Securities.

MOT is a global secondary battery assembly equipment manufacturing company. The cell manufacturing process of secondary batteries is divided into electrode, assembly, and activation processes, with MOT focusing on the assembly process, which requires customized technology tailored to cell specifications.

◆Witz= The expected public offering price range is KRW 5,300 to KRW 6,400, with a total public offering amount of KRW 15.9 billion to KRW 19.2 billion. Demand forecasting targeting institutional investors was conducted until the 1st, and public subscription will be held over two days on the 7th and 8th. The lead underwriter is Shinhan Investment Corp.

Witz supplies core solutions across all power transmission areas including mobile, wearable, and electric vehicles (EV). Since its establishment in 2019, it has been a key partner for Samsung Electronics’ wireless charging solutions, supplying wireless charging solutions to mobile devices such as the Galaxy S series and various wearable devices.

◆Synapsoft= The expected public offering price band is KRW 21,000 to KRW 24,500, with a total public offering amount of KRW 21.2 billion to KRW 24.7 billion. Demand forecasting will be conducted until the 4th, and general subscription will be held from the 8th to the 11th. The lead underwriter is NH Investment & Securities.

Founded in 2000, Synapsoft has proven to improve work productivity in the digital document utilization field, securing over 7,000 private companies including large corporations such as Samsung Electronics, SK, Hyundai, and LG, as well as 80% of government agencies as customers.